Literature DB >> 23338841

Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer-initiating cells.

Haobin Wang1, Sanyukta Rana, Nathalia Giese, Markus W Büchler, Margot Zöller.   

Abstract

Pancreatic adenocarcinoma (PaCa) being the deadliest cancer is partly due to early metastatic spread. Thus, we searched for PaCa-initiating cell (PaCIC) markers with emphasis on markers contributing to metastatic progression. PaCIC were enriched from long-term and freshly established lines by repeated selection for spheroid or holoclone growth in advance of evaluating PaCIC markers. Sphere and holoclone formation steeply increased by recloning and remained stable thereafter. Cells not forming spheres or holoclones died on recloning. PaCIC enrichment in spheres and holoclones was accompanied by increased motility, anchorage independence and upregulated CXCR4 expression. After subcutaneous injection in NOD/SCID mice tumorigenicity and, impressively, recovery of metastasizing tumor cells in peripheral blood, spleen, bone marrow, lung and pancreas was strongly increased in spheres and holoclones. PaCIC enrichment in spheres and holoclones was accompanied, besides CXCR4, by upregulated CD44v6, alpha6beta4, weakly CD133 and tetraspanin Tspan8 expression. Notably, CD44v6, alpha6beta4, CXCR4 and Tspan8 expressing PaCa cells had a growth advantage in vivo and became dominating in migrating and in distant organs settled tumor cells. This is the first report showing that CD44v6, alpha6beta4, Tspan8 and CXCR4 are biomarkers in PaCIC allowing for long-term survival, expansion and migration in immunocompromised mice. The stability of the percentage of PaCIC in long-term and freshly established lines after a roughly 8-fold enrichment by cloning indicates PaCIC, though required for long-term survival, concomitantly depending on support by non-CIC.
Copyright © 2013 UICC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23338841     DOI: 10.1002/ijc.28044

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

Review 1.  The key role of extracellular vesicles in the metastatic process.

Authors:  Hongyun Zhao; Abhinav Achreja; Elisabetta Iessi; Mariantonia Logozzi; Davide Mizzoni; Rossella Di Raimo; Deepak Nagrath; Stefano Fais
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-24       Impact factor: 10.680

Review 2.  Developments in miRNA gene signaling pathways in pancreatic cancer.

Authors:  Christina Vorvis; Marina Koutsioumpa; Dimitrios Iliopoulos
Journal:  Future Oncol       Date:  2016-03-17       Impact factor: 3.404

Review 3.  The role of pancreatic cancer-derived exosomes in cancer progress and their potential application as biomarkers.

Authors:  H Jin; Y Wu; X Tan
Journal:  Clin Transl Oncol       Date:  2017-02-06       Impact factor: 3.405

Review 4.  Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance.

Authors:  Laetitia Seguin; Jay S Desgrosellier; Sara M Weis; David A Cheresh
Journal:  Trends Cell Biol       Date:  2015-01-05       Impact factor: 20.808

Review 5.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

6.  TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway.

Authors:  Lunshou Wei; Yan Li; Zhimin Suo
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 7.  Pancreatic cancer diagnosis by free and exosomal miRNA.

Authors:  Margot Zöller
Journal:  World J Gastrointest Pathophysiol       Date:  2013-11-15

Review 8.  Extracellular vesicles as regulators of tumor fate: crosstalk among cancer stem cells, tumor cells and mesenchymal stem cells.

Authors:  Rafael Soares Lindoso; Federica Collino; Adalberto Vieyra
Journal:  Stem Cell Investig       Date:  2017-09-16

Review 9.  Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.

Authors:  Xu Zhang; Si Shi; Bo Zhang; Quanxing Ni; Xianjun Yu; Jin Xu
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

10.  Integrin-β4 is a novel transcriptional target of TAp73.

Authors:  Ningxia Xie; Polina Vikhreva; Margherita Annicchiarico-Petruzzelli; Ivano Amelio; Nicolai Barlev; Richard A Knight; Gerry Melino
Journal:  Cell Cycle       Date:  2018-02-08       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.